SERMs: Progress and future perspectives

Maturitas

Volumn 67, Issue 2, 2010, Pages 129-138

  Pickar, James H ^a   MacNeil, Tanya ^b   Ohleth, Kathleen ^b  

^a NewYork Presbyterian Hospital   (United States)

^b Precise Publications LLC   (United States)

Author keywords

Breast cancer; Hypogonadism; Menopause; Osteoporosis; SERM; TSEC

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; CENTCHROMAN; DROLOXIFENE; ESTROGEN RECEPTOR; IDOXIFENE; LASOFOXIFENE; OSPEMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; CONTRACEPTION; DIABETES MELLITUS; FRACTURE; HOT FLUSH; HUMAN; HYPOGONADISM; IN VITRO STUDY; INFERTILITY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; OVARY INSUFFICIENCY; POSTMENOPAUSE; PROSTATE CANCER; REVIEW; SCREENING; VAGINA ATROPHY; VERTEBRA FRACTURE;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 77956652851     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.05.009     Document Type: Review

References (131)

1. V.C. Jordan The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole Breast Cancer Res Treat 11 1988 197 209
2. D.N. Richardson The history of Nolvadex Drug Des Deliv 3 1988 1 14
3. M.P. Cole, C.T. Jones, and I.D. Todd A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474 Br J Cancer 25 1971 270 275
4. R.R. Love, R.B. Mazess, and H.S. Barden Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N Engl J Med 326 1992 852 856
5. J.F. Couse, and K.S. Korach Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20 1999 358 417
6. G.G. Kuiper, B. Carlsson, and K. Grandien Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta Endocrinology 138 1997 863 870 (Pubitemid 27089735)
7. C. Bolego, G. Rossoni, and G.P. Fadini Selective estrogen receptor-{alpha} agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action FASEB J 2010 [Epub ahead of print, March 9]
8. J. Sun, M.J. Meyers, B.E. Fink, R. Rajendran, J.A. Katzenellenbogen, and B.S. Katzenellenbogen Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta Endocrinology 140 1999 800 804
9. W.R. Harrington, S. Sheng, D.H. Barnett, L.N. Petz, J.A. Katzenellenbogen, and B.S. Katzenellenbogen Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression Mol Cell Endocrinol 206 2003 13 22
10. B.H. Norman, J.A. Dodge, and T.I. Richardson Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia J Med Chem 49 2006 6155 6157
11. H.A. Harris, L.M. Albert, and Y. Leathurby Evaluation of an estrogen receptor-beta agonist in animal models of human disease Endocrinology 144 2003 4241 4249
12. B.L. Riggs, and L.C. Hartmann Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N Engl J Med 348 2003 618 629
13. B.L. Riggs, and L.C. Hartmann Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N Engl J Med 348 2003 1192 1200
14. W. Feng, R.C. Ribeiro, and R.L. Wagner Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors Science 280 1998 1747 1749
15. L.A. Paige, D.J. Christensen, and H. Gron Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta Proc Natl Acad Sci USA 96 1999 3999 4004
16. A.M. Brzozowski, A.C. Pike, and Z. Dauter Molecular basis of agonism and antagonism in the oestrogen receptor Nature 389 1997 753 758
17. A.K. Shiau, D. Barstad, and P.M. Loria The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
18. J.D. Norris, L.A. Paige, and D.J. Christensen Peptide antagonists of the human estrogen receptor Science 285 1999 744 746
19. T.J. Berrodin, K.C. Chang, B.S. Komm, L.P. Freedman, and S. Nagpal Differential biochemical and cellular actions of premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination Mol Endocrinol 23 2009 74 85
20. K.C. Chang, Y. Wang, P.V. Bodine, S. Nagpal, and B.S. Komm Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens J Steroid Biochem Mol Biol 118 2010 117 124
21. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
22. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 2005 1652 1662
23. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451 1467
24. A.B. Grey, J.P. Stapleton, M.C. Evans, M.A. Tatnell, R.W. Ames, and I.R. Reid The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women Am J Med 99 1995 636 641
25. B. Kristensen, B. Ejlertsen, H.T. Mouridsen, K.W. Andersen, and J.B. Lauritzen Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen Breast Cancer Res Treat 39 1996 321 326
26. R.R. Love, D.A. Wiebe, and P.A. Newcomb Effects of tamoxifen on cardiovascular risk factors in postmenopausal women Ann Intern Med 115 1991 860 864
27. S.E. Reis, J.P. Costantino, D.L. Wickerham, E. Tan-Chiu, J. Wang, and M. Kavanah Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators J Natl Cancer Inst 93 2001 16 21
28. M. Baum, A.U. Budzar, and J. Cuzick Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
29. B. Thurlimann, A. Keshaviah, and A.S. Coates A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757
30. A.J. Chien, and P.E. Goss Aromatase inhibitors and bone health in women with breast cancer J Clin Oncol 24 2006 5305 5312
31. ® (toremifene citrate) Tablets. GTx, Inc.
32. H.A. Harvey, M. Kimura, and A. Hajba Toremifene: an evaluation of its safety profile Breast 15 2006 142 157
33. S. Pyrhonen, J. Ellmen, and J. Vuorinen Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer Breast Cancer Res Treat 56 1999 133 143
34. K. Holli, R. Valavaara, and G. Blanco Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group J Clin Oncol 18 2000 3487 3494
35. O. Pagani, S. Gelber, and K. Price Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 Ann Oncol 15 2004 1749 1759
36. C.L. Vogel, I. Shemano, J. Schoenfelder, R.A. Gams, and M.R. Green Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer J Clin Oncol 11 1993 345 350
37. A. Tiitinen, E. Nikander, P. Hietanen, M. Metsa-Heikkila, and O. Ylikorkala Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene Maturitas 48 2004 321 327
38. M. Kusama, K. Miyauchi, and H. Aoyama Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer Breast Cancer Res Treat 88 2004 1 8
39. ® (clomiphene citrate tablets USP). sanofi-aventis U S LLC.
40. S.L. Fitzpatrick, T.J. Berrodin, S.F. Jenkins, D.M. Sindoni, D.C. Deecher, and D.E. Frail Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line Endocrinology 140 1999 3928 3937
41. Clomiphene. Can Med Assoc J 1968;98:653-4.
42. M.M. Singh, and Centchroman. a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders Med Res Rev 21 2001 302 347
43. A. Kriplani, V. Kulshrestha, and N. Agarwal Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study J Obstet Gynaecol Res 35 2009 746 752
44. ® (raloxifene hydrochloride) Prescribing Information. Eli Lilly and Company.
45. ® (raloxifene hydrochloride) Summary of Product Characteristics. Eli Lilly and Company.
46. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
47. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
48. E. Barrett-Connor, L. Mosca, and P. Collins Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2006 125 137 (Pubitemid 44050394)
49. P. Collins, L. Mosca, and M.J. Geiger Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors Circulation 119 2009 922 930
50. K. Ensrud, A.R. Genazzani, and M.J. Geiger Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis Am J Cardiol 97 2006 520 527
51. S. Martino, D. Disch, S.A. Dowsett, C.A. Keech, and J.L. Mershon Safety assessment of raloxifene over eight years in a clinical trial setting Curr Med Res Opin 21 2005 1441 1452
52. A. DeMichele, A.B. Troxel, and J.A. Berlin Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study J Clin Oncol 26 2008 4151 4159
53. F.J. Cohen, and Y. Lu Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials Maturitas 34 2000 65 73
54. S. Palacios, M.L. Farias, and H. Luebbert Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate Am J Obstet Gynecol 191 2004 121 131
55. ® (lasofoxifene tartrate) 0.5 mg tablets, NDA 22-242, Reproductive Health Drugs Advisory Committee Briefing Document. September 8, 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4381b1-02-Pfizer.pdf. Accessed on February 20, 2010.
56. S.R. Cummings, K. Ensrud, and P.D. Delmas Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 2010 686 696
57. ® (lasofoxifene tartrate) Summary of Product Characteristics. Pfizer.
58. Final Summary Minutes, Advisory committe for reproductive health drugs meeting. September 8, 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/ 08/minutes/2008-4381m1-final.pdf. Accessed on March 15, 2010.
59. ® (bazedoxifene acetate) Summary of Product Characteristics. Pfizer.
60. S.L. Silverman, C. Christiansen, and H.K. Genant Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial J Bone Miner Res 23 2008 1923 1934
61. P.D. Miller, A.A. Chines, and C. Christiansen Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 2008 525 535
62. S. Ronkin, R. Northington, and E. Baracat Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women Obstet Gynecol 105 2005 1397 1404 (Pubitemid 40734275)
63. D.F. Archer, J.V. Pinkerton, and W.H. Utian Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women Menopause 16 2009 1109 1115
64. J.V. Pinkerton, D.F. Archer, and W.H. Utian Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis Menopause 16 2009 1102 1108
65. J. Baselga, A. Llombart-Cussac, and M. Bellet Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients Ann Oncol 14 2003 1383 1390
66. A. Buzdar, J.A. O'Shaughnessy, and D.J. Booser Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer J Clin Oncol 21 2003 1007 1014
67. V. Deshmane, S. Krishnamurthy, A.S. Melemed, P. Peterson, and A.U. Buzdar Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer J Clin Oncol 25 2007 4967 4973
68. Lilly Reports on Outcome of Phase III Study of Arzoxifene. August 18, 2009. Available at: http://www2.prnewswire.com/cgi-bin/micro-stories.pl?ACCT= 916306&TICK=LLY&STORY=/www/story/08-18-2009/0005079632&EDATE=Aug+18, +2009. Accessed on February 9, 2010.
69. A. Buzdar, D. Hayes, and A. El-Khoudary Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer Breast Cancer Res Treat 73 2002 161 175
70. G. Arpino, K.M. Nair, D.C. Doval, V.J. Bardou, G.M. Clark, and R.M. Elledge Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer Ann Oncol 14 2003 233 241
71. S.L. Hendrix, and S.G. McNeeley Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium Ann NY Acad Sci 949 2001 243 250
72. S.R. Goldstein, and N. Nanavati Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study Am J Obstet Gynecol 187 2002 521 527
73. S.R. Jackson, N.C. Avery, J.F. Tarlton, S.D. Eckford, P. Abrams, and A.J. Bailey Changes in metabolism of collagen in genitourinary prolapse Lancet 347 1996 1658 1661 (Pubitemid 26177387)
74. S.R. Goldstein, P. Neven, L. Zhou, Y.L. Taylor, A.V. Ciaccia, and L. Plouffe Raloxifene effect on frequency of surgery for pelvic floor relaxation Obstet Gynecol 98 2001 91 96
75. L.M. Helvering, M.D. Adrian, and A.G. Geiser Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus Biol Reprod 72 2005 830 841
76. D.A. Cox, and L.M. Helvering Extracellular matrix integrity: a possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens? Mol Cell Endocrinol 247 2006 53 59
77. E.M. Rutanen, J. Heikkinen, K. Halonen, J. Komi, R. Lammintausta, and O. Ylikorkala Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial Menopause 10 2003 433 439
78. J. Komi, K.S. Lankinen, and P. Harkonen Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women Menopause 12 2005 202 209
79. J. Komi, J. Heikkinen, E.M. Rutanen, K. Halonen, R. Lammintausta, and O. Ylikorkala Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women Gynecol Endocrinol 18 2004 152 158
80. O. Ylikorkala, B. Cacciatore, and K. Halonen Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women Menopause 10 2003 440 447
81. G.A. Bachmann, and J.O. Komi Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study Menopause 2009 [Epub ahead of print, December 20]
82. Quatrx Pharmaceuticals Reports Positive Results of a Second Pivotal Phase 3 Clinical Study for Ophena™ (Ospemiphene Tablets) in Treatment of Postmenopausal Vaginal Atrophy. September 10, 2009. Available at: http://www.quatrx.com/news/09-10-09.htm. Accessed on March 1, 2010.
83. Quatrx Announces Further Positive Phase 3 Results for Ophena™ (Ospemiphene Tablets) in Treatment of Postmenopausal Vaginal Atrophy. July 29, 2009. Available at: http: http://www.quatrx.com/news/07-29-09.htm. Accessed on March 1, 2010.
84. T.E. Vogelvang, V. Mijatovic, P. Kenemans, T. Teerlink, and M.J. van der Mooren HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women Fertil Steril 82 2004 1540 1549
85. T.E. Vogelvang, V. Mijatovic, P. Kenemans, C.G. Schalkwijk, and M.J. van der Mooren Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women Am J Cardiol 94 2004 1205 1208
86. T.E. Vogelvang, V. Mijatovic, P. Kenemans, J.J. Emeis, J.A. Heijst, and M.J. van der Mooren The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women Am J Obstet Gynecol 193 2005 1384 1394
87. T.E. Vogelvang, J.R. Leurs, V. Mijatovic, J. Willemse, and M.J. van der Mooren HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women. Thromb Haemost 3 2005 1090 1092
88. Radius initiates phase 2a clinical trial of RAD1901 in menopausal hot flashes. March 24, 2009. Available at: http://www.radiuspharm.com/RAD1901.Ph2a. 3.24.09.pdf. Accessed on March 1, 2010.
89. S.Y. Dai, M.J. Chalmers, and J. Bruning Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method Proc Natl Acad Sci USA 105 2008 7171 7176
90. J.H. Pickar, I.-T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil Steril 92 2009 1018 1024
91. D.W. Stovall, W. Utian, and M. Gass The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety Menopause 14 2007 510 517
92. S.R. Davis, S.M. O'Neill, and J. Eden Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium - a pilot study Menopause 11 2004 167 175
93. S. Carranza-Lira, A.L. Gooch, N. Saldivar, and M.S. Osterwalder Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses Int J Fertil Womens Med 52 2007 93 96
94. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women Fertil Steril 92 2009 1045 1052
95. R.A. Lobo, J.V. Pinkerton, and M.L.S. Gass Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile Fertil Steril 92 2009 1025 1038
96. D.F. Archer, V. Lewis, B.R. Carr, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil Steril 92 2009 1039 1044
97. J.V. Pinkerton, W.H. Utian, G.D. Constantine, S. Olivier, and J.H. Pickar Relief of vasomotor symptoms with the tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 16 2009 1116 1124
98. R. Kagan, R.S. Williams, K. Pan, S. Mirkin, and J.H. Pickar A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 17 2010 281 289
99. L.J. Melton III, E.A. Chrischilles, C. Cooper, A.W. Lane, B.L. Riggs, and Perspective How many women have osteoporosis? J Bone Miner Res 7 1992 1005 1010
100. S. Amin, Y. Zhang, and D.T. Felson Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study Am J Med 119 2006 426 433
101. D. Mellstrom, L. Vandenput, and H. Mallmin Older men with low serum estradiol and high serum SHBG have an increased risk of fractures J Bone Miner Res 23 2008 1552 1560
102. S. Khosla Update in male osteoporosis J Clin Endocrinol Metab 95 2010 3 10
103. A. Falahati-Nini, B.L. Riggs, E.J. Atkinson, W.M. O'Fallon, R. Eastell, and S. Khosla Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 106 2000 1553 1560
104. B. Uebelhart, F. Herrmann, I. Pavo, M.W. Draper, and R. Rizzoli Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels J Bone Miner Res 19 2004 1518 1524
105. P.M. Doran, B.L. Riggs, E.J. Atkinson, and S. Khosla Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men J Bone Miner Res 16 2001 2118 2125
106. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
107. M.R. Smith, M.A. Fallon, H. Lee, and J.S. Finkelstein Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 2004 3841 3846
108. M.R. Smith, S.B. Malkowicz, and F. Chu Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study J Urol 179 2008 152 155
109. M.R. Smith, S.B. Malkowicz, and F. Chu Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study J Clin Oncol 26 2008 1824 1829
110. Gtx's Toremifene citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostrate Cancer Patients on Androgen Deprivation Therapy. February 25, 2008. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c= 148196&p=irol-newsArticle&ID=1111644&highlight=/. Accessed on February 26, 2010.
111. GTx's Toremifene 80 mg Increased Bone Mineral Density in Multiple Clinically Relevant Subpopulations of Prostate Cancer on Androgen Deprivation Therapy. June 1, 2009. Available at: http://phx.corporate-ir.net/phoenix.zhtml? c=148196&p=irol-newsArticle&ID=1294185&highlight=/. Accessed on February 22, 2010.
112. S.M. Ho Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates J Cell Biochem 91 2004 491 503
113. G.K. Lefkowitz, S.S. Taneja, J. Brown, J. Melamed, and H. Lepor Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels J Urol 168 2002 1415 1418
114. S.S. Taneja, M.R. Smith, and J.T. Dalton Toremifene - a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy Expert Opin Investig Drugs 15 2006 293 305
115. D. Price, B. Stein, and P. Sieber Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial J Urol 176 2006 965 970
116. GTx Announces Top Line Results of Phase III Clinical Trial Evaluating Toremifene 20 mg for the Prevention of Prostate Cancer in Men with High Grade PIN. May 25, 2010. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c= 148196&p=irol-newsArticle&ID=1430998&highlight=/. Accessed on May 26, 2010.
117. S. Hill, V. Arutchelvam, R. Quinton, and Enclomiphene an estrogen receptor antagonist for the treatment of testosterone deficiency in men IDrugs 12 2009 109 119
118. ® in Hypogonadal Men. January 27, 2010. Available at: http://www.businesswire.com/portal/site/repros/. Accessed on March 1, 2010.
119. J. Kaminetsky, and M.L. Hemani Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency Expert Opin Investig Drugs 18 2009 1947 1955
120. ®) decreases serum glucose in men with idiopathic hypogonadotrophic hypogonadism Poster presented at the Annual Meeting of the Endocrine Society in San Francisco California, June14-18 2008
121. ® in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective. February 2, 2010. Available at: http://www.businesswire.com/portal/ site/repros/. Accessed on March 1, 2010.
122. E.L. Ding, Y. Song, V.S. Malik, and S. Liu Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis JAMA 295 2006 1288 1299
123. A.E. Heufelder, F. Saad, M.C. Bunck, and L. Gooren Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone J Androl 30 2009 726 733
124. D. Kapoor, E. Goodwin, K.S. Channer, and T.H. Jones Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes Eur J Endocrinol 154 2006 899 906
125. G. Cavallini Male idiopathic oligoasthenoteratozoospermia Asian J Androl 8 2006 143 157
126. D.A. Adamopoulos, A. Pappa, E. Billa, S. Nicopoulou, E. Koukkou, and J. Michopoulos Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia Fertil Steril 80 2003 914 920
127. D.A. Adamopoulos, S. Nicopoulou, N. Kapolla, M. Karamertzanis, and E. Andreou The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia Fertil Steril 67 1997 756 762
128. D. Farmakiotis, C. Farmakis, D. Rousso, A. Kourtis, I. Katsikis, and D. Panidis The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia Fertil Steril 88 2007 847 853
129. E. Tsourdi, A. Kourtis, D. Farmakiotis, I. Katsikis, M. Salmas, and D. Panidis The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia Fertil Steril 91 2009 1427 1430
130. E. Yatkin, J. Bernoulli, R. Lammintausta, R. Santti, and Fispemifene [Z-2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis J Pharmacol Exp Ther 327 2008 58 67
131. Quatrx Pharmaceuticals Reports Positive Results From a Phase 2 Trial of Fispemifene. January 8, 2007. Available at: http://www.quatrx.com/news/01-08-07. htm. Accessed on March 1, 2010.